HTG Molecular Diagnostics, a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced the completion of its previously announced public offering of 1,290,322 shares of common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase up to The Series A-1 warrants have an exercise price of $7.50 per share, are immediately exercisable, and will expire five years from the date of issuance, while the Series A-2 warrants have an exercise price of $7.50 per share, are immediately exercisable, and will expire five years from the date of issuance.
The offering’s exclusive placement agent was H.C. Wainwright & Co.
Before subtracting the placement agent’s fees and other offering charges, the gross proceeds from the offering are approximately $10.0 million. The net proceeds of this offering will be used for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures, and working capital.
The securities described above were offered in accordance with a registration statement on Form S-1 (File No. 333-268681), which the Securities and Exchange Commission (the “SEC”) declared effective on December 21, 2022. Only a prospectus, which is part of the valid registration statement, was used to make the offering. A final prospectus for the offering has been filed with the SEC.
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery
